Saturday, October 31, 2026

Himax Technologies And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team

September 17, 2021

Himax Technologies  And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

(VIANEWS) - Himax Technologies (HIMX), BancorpSouth (BXS), ABB Ltd (ABB) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Himax Technologies (HIMX)

63.2% sales growth and 41.18% return on equity

Himax Technologies, Inc., a fabless semiconductor company, provides display imaging processing technologies in China, Taiwan, the Philippines, Korea, Japan, Europe, and the United States.

Himax Technologies's sales growth this year is expected to be 57.8% and 9.9% for next year.

Year-on-year quarterly revenue growth grew by 95.3%, now sitting on 1.19B for the twelve trailing months.

Volume

Today's last reported volume for Himax Technologies is 2144330 which is 46.51% below its average volume of 4009160.

Himax Technologies's sales growth is a negative 0% for the present quarter and 63.2% for the next. The company's growth estimates for the current quarter and the next is 1042.9% and 345%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 41.18%.

Volatility

Himax Technologies's last day, last week, and last month's current volatility was 9.74%, 3.26%, and 3.01%, respectively.

Himax Technologies's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 5.04% (day), 4.43% (last week), and 4.80% (last month), respectively.

Himax Technologies's Stock Yearly Top and Bottom Value

Himax Technologies's stock is valued at $11.40 at 20:22 EST, way below its 52-week high of $17.88 and way higher than its 52-week low of $3.28.

Himax Technologies's Moving Average

Himax Technologies's value is way under its 50-day moving average of $12.84 and way under its 200-day moving average of $13.16.

2. BancorpSouth (BXS)

57.4% sales growth and 10.33% return on equity

BancorpSouth Bank provides commercial banking and financial services to individuals and small-to-medium size businesses.

BancorpSouth's sales growth this year is anticipated to be 16.8% and 47.1% for next year.

Year-on-year quarterly revenue growth grew by 11.9%, now sitting on 1.03B for the twelve trailing months.

Volume

Today's last reported volume for BancorpSouth is 1028290 which is 10.71% above its average volume of 928801.

BancorpSouth's sales growth for the next quarter is 57.4%. The company's growth estimates for the current quarter and the next is a negative 7.2% and negative -155.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.33%.

Volatility

BancorpSouth's last day, last week, and last month's current volatility was 0.79%, 0.96%, and 1.08%, respectively.

BancorpSouth's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.20% (day), 1.61% (last week), and 2.15% (last month), respectively.

BancorpSouth's Stock Yearly Top and Bottom Value

BancorpSouth's stock is valued at $29.22 at 20:22 EST, way below its 52-week high of $35.59 and way above its 52-week low of $18.11.

BancorpSouth's Moving Average

BancorpSouth's value is higher than its 50-day moving average of $27.97 and below its 200-day moving average of $29.78.

Previous days news about BancorpSouth(BXS)

  • According to CNBC on Wednesday, 15 September, "In a 2016 complaint, the Consumer Financial Protection Bureau alleged that BancorpSouth unlawfully denied Memphis-area Black applicants certain mortgage loans. "

3. ABB Ltd (ABB)

9.8% sales growth and 7.18% return on equity

ABB Ltd manufactures and sells electrification, industrial automation, motion, and robotics and discrete automation products for customers in utilities, industry and transport, and infrastructure worldwide.

ABB Ltd's sales growth this year is expected to be 13.5% and 5.5% for next year.

Year-on-year quarterly revenue growth grew by 21%, now sitting on 28.11B for the twelve trailing months.

Volume

Today's last reported volume for ABB Ltd is 704885 which is 42.55% below its average volume of 1227080.

ABB Ltd's sales growth for the next quarter is 9.8%. The company's growth estimates for the present quarter and the next is 90.5% and 57.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.18%.

Volatility

ABB Ltd's last day, last week, and last month's current volatility was 0.43%, 0.72%, and 0.66%, respectively.

ABB Ltd's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.10% (day), 0.91% (last week), and 0.82% (last month), respectively.

ABB Ltd's Stock Yearly Top and Bottom Value

ABB Ltd's stock is valued at $36.61 at 20:22 EST, below its 52-week high of $38.03 and way above its 52-week low of $24.07.

ABB Ltd's Moving Average

ABB Ltd's value is below its 50-day moving average of $37.20 and above its 200-day moving average of $34.16.

4. AptarGroup (ATR)

7.4% sales growth and 14.1% return on equity

AptarGroup, Inc. provides a range of packaging, dispensing, and sealing solutions primarily for the beauty, personal care, home care, prescription drug, consumer health care, injectable, and food and beverage markets.

AptarGroup's sales growth this year is anticipated to be 9.5% and 5.5% for next year.

Year-on-year quarterly revenue growth grew by 16%, now sitting on 3.1B for the twelve trailing months.

Volume

Today's last reported volume for AptarGroup is 340776 which is 56.83% above its average volume of 217277.

AptarGroup's sales growth for the next quarter is 7.4%. The company's growth estimates for the current quarter and the next is a negative 5% and 9.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.1%.

Volatility

AptarGroup's last day, last week, and last month's current volatility was 2.22%, 1.45%, and 0.73%, respectively.

AptarGroup's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.77% (day), 1.90% (last week), and 1.35% (last month), respectively.

AptarGroup's Stock Yearly Top and Bottom Value

AptarGroup's stock is valued at $125.84 at 20:22 EST, way below its 52-week high of $158.97 and way above its 52-week low of $110.34.

AptarGroup's Moving Average

AptarGroup's value is under its 50-day moving average of $132.35 and way under its 200-day moving average of $140.95.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com